RENO, Nev., July 24, 2026 (KOREWIRE) ... Sarcomatrix Therapeutics Corp., a Delaware corporation based in Reno, Nevada, today announced that its investment round is open to accredited investors. The round is being conducted under Regulation D, Rule 506(c), and is available through the Investors section of the company's website. The offering runs on the KoreConX platform, with KoreTransfer USA LLC acting as transfer agent.
Sarcomatrix is a preclinical-stage company, which means its treatments have not yet been tested in people. The company is working toward that step now, and expects to ask the U.S. Food and Drug Administration for permission to begin human testing in early 2027.
The problem: a disease that takes muscle away, a little at a time
Duchenne muscular dystrophy is a genetic disease that mostly affects boys. It shows up in early childhood. A protein that normally protects muscle fibers is missing, so ordinary movement slowly tears the muscle apart faster than the body can repair it. Most patients lose the ability to walk in their teens. The disease eventually affects the muscles used to breathe and the heart.
There is no cure. The treatments that do exist help some patients, but there is a catch that most people outside the field do not know about.
The catch: most treatments only work for a slice of patients
Duchenne is not caused by one single genetic error. It is caused by thousands of different errors in the same gene. Scientists have identified more than 7,000 distinct mutations in that one gene. And Duchenne is only one form of the disease. Muscular dystrophy is really an umbrella term covering more than 30 separate genetic conditions, with more than 10,000 disease-causing mutations catalogued across all of them.*
Most treatments in development are built to correct one specific error. That means each drug can only help the patients who happen to have that particular error. A given drug may reach only a small fraction of patients. Everyone else waits for a different drug that may never be developed, because the numbers for their specific mutation are too small to justify the cost.
This is the gap Sarcomatrix is aiming at.
The approach: work with the muscle, not around the mutation
Sarcomatrix's lead candidate, called S-969, is what the industry calls a novel, first-in-class drug, meaning it works by a mechanism no approved treatment currently uses. Instead of trying to fix the broken gene, it targets a separate protein called alpha-7 beta-1 integrin. That protein does two useful jobs at once. It acts like an anchor, helping hold muscle fibers to the surrounding tissue so they are less likely to tear. It also acts as a signal, supporting the muscle's own natural repair process.
Because this approach does not depend on which mutation a patient has, it is designed to be relevant across the patient population rather than one subgroup. The industry term for this is mutation-agnostic. S-969 is being developed as an oral pill taken once a day, for Duchenne muscular dystrophy, Becker muscular dystrophy, and a related condition called limb-girdle muscular dystrophy type 2I/R9.
Where the company stands today
Sarcomatrix has completed laboratory and animal research and is now preparing for human trials. The company's stated plan is to file its application with the FDA in the first quarter of 2027, begin first-in-human dosing in the second quarter of 2027 at Nucleus Network in Melbourne, Australia, and reach an initial readout on whether the drug is working in patients by late 2028. These are plans, not guarantees, and drug development frequently takes longer than expected or fails outright.
• Backed by outside investors already. Existing investors include Prevail Partners as a co-lead, Battle Born Venture (Nevada's state-sponsored venture capital program), and Research Affiliates Capital.
• Roughly $8.9 million invested to date, including non-dilutive research funding from the National Institutes of Health.
• A second program with special regulatory status. LAM-111, for a rare form of congenital muscular dystrophy, has been granted Orphan Drug Designation in both the United States and the European Union. That status is given to treatments for rare diseases and can bring development incentives.
• A university-born science base. The company is a spinout of the University of Nevada, Reno, and holds its programs under a worldwide exclusive license through the Nevada Research and Innovation Corporation. More than 75 patents have been filed.
• Insurance being arranged to help cover clinical trial costs through Acrisure Re/ARCAS, underwritten by MCI on Lloyd's Syndicate 1902.
• An Orphan Drug Designation application for S-969 is in progress.
The market today, and where it is heading
Independent market analyses estimate the global Duchenne muscular dystrophy treatment market at roughly $3 billion to $5 billion today, with projections in the range of $8 billion to $12 billion by 2030 as gene therapies and other new treatments reach more patients.**
The company estimates an initial commercial population of approximately 30,000 patients across the United States, Canada, and Western Europe, within a broader addressable population of approximately 48,000 across North America and Europe, and more than 300,000 worldwide.***
Looking beyond 2030, published forecasts extending to 2035 continue to show growth in this market. Sarcomatrix also believes the biology underlying S-969, supporting the muscle's own repair process, may have relevance in other conditions involving muscle loss. Those additional indications are not currently in development, no regulatory filings have been made for them, and the company may never pursue them.
IMPORTANT: These figures describe the size of the overall market, not Sarcomatrix revenue. Sarcomatrix has no approved products and no product revenue. It may never obtain regulatory approval, and it may never capture any share of this market. Market size is not a forecast of company performance and should not be read as one.
From the company
"Families living with Duchenne are running a clock that does not stop while the science catches up," said David Craig, Co-Founder, President, and Chief Executive Officer. "We are getting close to the point where this stops being laboratory work and becomes a real trial in real patients. That is the hardest and most important step a company like ours takes, and it is the step this round is meant to fund."
"Targeting alpha-7 beta-1 integrin means working with the muscle's own repair machinery rather than around a single mutation," said Dean Burkin, PhD, Co-Founder and Chairman, whose laboratory at the University of Nevada, Reno originated the science. "That is what makes this approach potentially relevant across these diseases rather than to one small genetic subset."
Before you consider investing, understand the risks
|
This is an early-stage company. Sarcomatrix has no approved products, no product revenue, and its treatments have never been tested in humans. Most experimental drugs fail. The large majority of drug candidates that enter human testing never reach the market. Promising results in the laboratory or in animals often do not carry over to people. You could lose your entire investment. This is a realistic outcome in early-stage biotechnology, not a remote one. You cannot easily sell these shares. There is no public market for them, and none is expected to develop. Your money may be tied up indefinitely. Timelines slip. The 2027 and 2028 dates in this release are goals. Regulatory delays, manufacturing problems, and funding gaps commonly push them back. Only invest what you can afford to lose entirely. |
How to participate
This offering is open only to accredited investors, a category defined by the U.S. Securities and Exchange Commission based on income, net worth, or professional credentials. Under Rule 506(c), a company must take reasonable steps to confirm that status. Simply saying you qualify is not enough. Verification is handled through the offering platform as part of the sign-up process.
Accredited investors can review the offering and start verification at sarcomatrix.com/investors, or go directly to sarcomatrix.com/invest. Full offering terms, subscription documents, and complete risk disclosures are provided on the KoreConX platform once accredited status has been verified. The round is scheduled to close September 30, 2026, subject to earlier closing if fully subscribed or extension at the Company's discretion.
About Sarcomatrix Therapeutics Corp.
Sarcomatrix Therapeutics Corp., a Delaware corporation headquartered in Reno, Nevada, is a preclinical-stage company developing novel, first-in-class treatments for rare muscle-wasting diseases, including Duchenne muscular dystrophy, Becker muscular dystrophy, LGMD2I/R9, and LAMA2-related congenital muscular dystrophy. A spinout of the University of Nevada, Reno, the company holds its programs under a worldwide exclusive license through the Nevada Research and Innovation Corporation. Learn more at sarcomatrix.com.
Investor Relations
Ray Jordan
President, Investor Relations and Public Relations
Putnam Insights
ir@sarcomatrix.com
* Type counts per Cleveland Clinic and NYU Langone classifications of muscular dystrophy. Dystrophin gene variant counts per the TREAT-NMD Global Database and the Leiden Open Variation Database, which report more than 7,000 reported variants. The figure of more than 10,000 refers to catalogued disease-causing variants across the muscular dystrophies collectively, not the Duchenne gene alone. ** Market figures reflect the range of published third-party estimates for the Duchenne muscular dystrophy treatment market, including Grand View Research, Mordor Intelligence, Market Research Future, and DataM Intelligence. Estimates vary by methodology and scope. *** Patient population figures are company estimates. The 30,000 figure is the initial commercial population for the United States, Canada, and Western Europe; 48,000 is the addressable population for North America and Europe; the global figure reflects worldwide totals across the indications under development.
Forward-Looking Statements
This release contains forward-looking statements, including statements about product candidates, development and regulatory plans, anticipated timelines for FDA filing, first-in-human dosing and clinical readouts, market size and growth estimates, patient population estimates, potential additional indications, intellectual property, and the arrangement of clinical trial funding insurance. These statements involve significant risks and uncertainties, including the risks inherent in preclinical and clinical drug development, regulatory review, financing, and commercialization. Actual results may differ materially. Product candidates are investigational, have not been approved by any regulatory authority, and are not available for sale. Results in the laboratory or in animals are not necessarily predictive of results in humans. Market and patient population estimates are based on third-party sources and company assumptions, may prove inaccurate, and do not represent any projection of company revenue or market share. Forward-looking statements speak only as of the date made, and the company undertakes no obligation to update them except as required by law.
Offering Disclaimer
This communication is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any offer or sale of securities is made solely pursuant to Rule 506(c) of Regulation D under the Securities Act of 1933, as amended, and only to persons whose status as accredited investors has been verified. The securities have not been registered under the Securities Act or any state securities laws and are offered in reliance on exemptions from registration. No securities regulator has approved or passed upon the merits of this offering or the accuracy of any offering materials. Investment in an early-stage, preclinical biotechnology company involves a high degree of risk, including the possible loss of the entire investment. There is no public market for these securities and none is expected to develop. Prospective investors should review the offering materials in full and consult their own legal, tax, and financial advisors before investing.
###
